|
12 Sep 2025 |
Zydus Lifesciences
|
Consensus Share Price Target
|
1044.75 |
1006.63 |
- |
-3.65 |
hold
|
|
|
|
|
06 Feb 2023
|
Zydus Lifesciences
|
Prabhudas Lilladhar
|
1044.75
|
480.00
|
470.15
(122.22%)
|
Target met |
Accumulate
|
|
|
|
|
06 Feb 2023
|
Zydus Lifesciences
|
ICICI Securities Limited
|
1044.75
|
482.00
|
434.65
(140.37%)
|
Target met |
Accumulate
|
|
|
Zydus Lifesciences’ (Zydus) reported Q3FY23 performance exceeded our estimates on all fronts. Revenues grew 19.4% YoY to Rs43.6bn (I-Sec: Rs40.7bn) driven by India and US markets.
|
|
04 Feb 2023
|
Zydus Lifesciences
|
Motilal Oswal
|
1044.75
|
460.00
|
434.00
(140.73%)
|
Target met |
Neutral
|
|
|
|
|
04 Feb 2023
|
Zydus Lifesciences
|
ICICI Direct
|
1044.75
|
500.00
|
434.65
(140.37%)
|
Target met |
Buy
|
|
|
|
|
02 Jan 2023
|
Zydus Lifesciences
|
Ashika Research
|
1044.75
|
480.00
|
420.10
(148.69%)
|
Target met |
Buy
|
|
|
|
|
14 Nov 2022
|
Zydus Lifesciences
|
ICICI Direct
|
1044.75
|
480.00
|
423.80
(146.52%)
|
Target met |
Hold
|
|
|
|
|
14 Nov 2022
|
Zydus Lifesciences
|
Prabhudas Lilladhar
|
1044.75
|
465.00
|
416.75
(150.69%)
|
Target met |
Accumulate
|
|
|
|
|
14 Nov 2022
|
Zydus Lifesciences
|
ICICI Securities Limited
|
1044.75
|
448.00
|
423.80
(146.52%)
|
Target met |
Hold
|
|
|
Zydus Lifesciences (Zydus) reported Q2FY23 performance is broadly in line with our estimates. Revenue grew 7.3% YoY to Rs40.0bn (I-Sec: Rs40.0bn) on the back of India and US markets.
|
|
12 Nov 2022
|
Zydus Lifesciences
|
Motilal Oswal
|
1044.75
|
410.00
|
423.80
(146.52%)
|
Target met |
Neutral
|
|
|
|
|
13 Aug 2022
|
Zydus Lifesciences
|
ICICI Direct
|
1044.75
|
405.00
|
386.85
(170.07%)
|
Target met |
Hold
|
|
|
|